LONDON, April 8, 2014 /PRNewswire/ --
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite
closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average
ending the session at 16,245.87, down 1.02%, and the S&P 500
edging 1.08% lower to finish the trading session at 1,845.04. The
losses were broad based as nine out of 10 sectors ended the session
in negative. A number of stocks saw large movements, including
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios
Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc.
(NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
Free technical research on PPHM, AGIO, IDIX and LXRX can be
downloaded upon signing up at:
http://www.investor-edge.com/914-register
Shares in Peregrine Pharmaceuticals Inc. edged 2.72% higher,
finishing Monday's session at $1.89.
The stock fluctuated between $1.88 and
$2.09 during the session with a trading volume of 6.75
million shares as compared with its three months average volume of
5.10 million shares. Shares in Peregrine Pharmaceuticals Inc. have
fallen by 21.25% in the last one month, while the stock has surged
19.62% in the previous three months and 35.97% on YTD basis. The
S&P 500 Health Care Sector Index mapped a loss of 1.06% during
the trading session and charted up 3.19% in the previous three
months. Furthermore, the company's stock has a Relative Strength
Index (RSI) of 42.16 and is trading above its 200-day moving
average of $1.55. Sign up today to
read free research on PPHM at:
http://www.investor-edge.com/914-PPHM-08Apr2014.pdf
On Monday, shares in Agios Pharmaceuticals Inc. ended the session
at $45.35, up 27.82%. A total of 2.69
million shares were traded as compared with its three months
average volume of 0.36 million shares. During the session, the
stock traded between $41.37 and
$46.00. Agios Pharmaceuticals Inc.'s shares have rallied
23.97% in the past three trading sessions, 88.96% in the previous
three months and 89.35% on YTD basis. The S&P 500 Health Care
Sector Index mapped a loss of 1.06% during the trading session and
has declined 3.26% in the last one month. Further, the company's
stock has an RSI of 44.90 and is trading above its 50-day moving
average of $34.73. On Sunday, April 6, 2014, the company announced that
data from its lead, first-in-class program AG-221 will be presented
at a Clinical Trials Symposium. These preliminary data demonstrate
the clinical activity, tolerability and unique mechanism of action
of AG-221 in patients with advanced hematologic malignancies with
an isocitrate dehydrogenase-2 (IDH2) mutation. Sign up today to
read free research on AGIO at:
http://www.investor-edge.com/914-AGIO-08Apr2014.pdf
Idenix Pharmaceuticals Inc.'s stock finished Monday's session at
$5.81, up 12.38%. A total of 4.19
million shares were traded which is above its three months average
volume of 1.54 million shares. The stock vacillated between
$5.12 and $5.96 during the session.
Idenix Pharmaceuticals Inc.'s shares have lost 12.37% in the last
one month and 2.84% on YTD basis. The S&P 500 Health Care
Sector Index mapped a loss of 1.06% during the trading session, and
has fallen by 2.85% in the previous three trading sessions.
Additionally, the company's stock has an RSI of 30.86 and is
trading above its 200-day moving average of $5.26. On the same day, the company announced
continued progress of the Company's program to develop nucleotide
prodrug inhibitors for the treatment of hepatitis C virus (HCV)
infection. Sign up today to read free research on IDIX at:
http://www.investor-edge.com/914-IDIX-08Apr2014.pdf
Shares in Lexicon Pharmaceuticals Inc. closed Monday's session at
$1.64, up 3.14%, after hitting a new
52-week low of $1.54. The stock
oscillated between $1.54 and $1.68
during the trading session with a trading volume of 2.00 million
shares, which is above its three months average volume of 1.21
million shares. Shares in Lexicon Pharmaceuticals Inc. have
declined 8.38% in the last one month and 8.84% on YTD basis. The
S&P 500 Health Care Sector Index mapped a loss of 1.06% during
the trading session, while the same has charted up 3.19% in the
last three months. Moreover, the company's stock has an RSI of
37.38 and is trading below its 50-day and 200-day moving averages
of $1.79 and $2.16, respectively. Sign up today to read free
research on LXRX at:
http://www.investor-edge.com/914-LXRX-08Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge